Right now I think the first choice is Sanofi-Aventis. With the results of the clinical trials they can market the Lantus/Afrezza combination as a complete therapy for Type 1 diabetes, and the only one that has been fully tested. I could even see them using the marketing to drive sales of Lantus by not promoting the use of Afrezza with other basal insulins, especially if Afrezza is initially in short supply. IMO MannKind needs a marketing partner, but they have plenty to offer in return.